Skip to main content
Medical information Clinical review pending

Infection Testing

Malaria P Vivax Quantitative Test

Detects and quantifies the Plasmodium vivax malaria parasite in your blood, aiding in diagnosis and treatment monitoring.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Whole blood or dried blood spot.
Results
Results typically available within 24-36 hours. Confirm with the laboratory before booking.
Preparation
No specific preparation is required. Patients must sign a consent form and provide relevant clinical history.
Test priceKSh 12,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Malaria P Vivax Quantitative Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of malaria (fever, chills, headache, nausea)
  • ✓Travel history to malaria-endemic regions
  • ✓Exposure to individuals with malaria
  • ✓Monitoring treatment effectiveness
  • ✓Diagnosis in areas with Plasmodium vivax prevalence
02

In plain language

What this test helps you understand

This test helps diagnose Plasmodium vivax malaria, assess infection severity, and monitor treatment response.
The Malaria P Vivax Quantitative Test is a diagnostic tool used to identify the presence and amount of the Plasmodium vivax parasite in a blood sample. This test is important for diagnosing malaria, especially in areas where it is common, like Kenya. Early detection allows for prompt treatment, which can prevent serious health problems.

This test measures the number of Plasmodium vivax parasites in your blood. Knowing the parasite load helps doctors understand the severity of the infection and track how well treatment is working.

Individuals experiencing malaria symptoms like fever, chills, headache, nausea, or vomiting should consider this test. People who have recently traveled to malaria-prone areas or have been exposed to infected individuals are also advised to get tested.

Benefits of this test include early diagnosis for timely treatment, monitoring treatment effectiveness, reducing the risk of severe malaria complications, and providing reassurance regarding potential infection.

Your test results will show if the Plasmodium vivax parasite is present and in what quantity. A healthcare provider will interpret these results and discuss the next steps, including treatment if needed. Discussing your results with your doctor is crucial for understanding their meaning.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific preparation is required. Patients must sign a consent form and provide relevant clinical history.
SampleWhole blood or dried blood spot.
MethodologyMolecular methods (e.g., PCR) are typically used to quantify parasite DNA.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically detects Plasmodium vivax. Other malaria species may not be detected. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test detects and quantifies the Plasmodium vivax parasite, a specific type of malaria parasite.
Quantifying the parasite load helps assess the severity of the infection and monitor how well treatment is working.
Individuals with malaria symptoms, those who have traveled to malaria-risk areas, or those exposed to infected individuals should consider this test.
Results indicate the presence and quantity of the parasite. A healthcare provider will interpret the results.
No specific preparation is needed, but you will need to sign a consent form and provide your medical history.
Results are typically available within 24-36 hours. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp